{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:52:34Z","timestamp":1793508754267,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973271"],"award-info":[{"award-number":["81973271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jconrel.2021.06.027","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T06:26:16Z","timestamp":1624515976000},"page":"393-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy"],"prefix":"10.1016","volume":"337","author":[{"given":"Cong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiujun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuizhong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.jconrel.2021.06.027_bb0005","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.jconrel.2021.06.027_bb0010","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.jconrel.2021.06.027_bb0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jconrel.2021.06.027_bb0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2017.10.027","article-title":"Cancer evolution during immunotherapy","volume":"171","author":"Andrews","year":"2017","journal-title":"Cell"},{"issue":"28","key":"10.1016\/j.jconrel.2021.06.027_bb0025","doi-asserted-by":"crossref","first-page":"1801120","DOI":"10.1002\/smll.201801120","article-title":"A multifunctional biomimetic nanoplatform for relieving hypoxia to enhance chemotherapy and inhibit the PD-1\/PD-L1 axis","volume":"14","author":"Zou","year":"2018","journal-title":"Small"},{"issue":"7","key":"10.1016\/j.jconrel.2021.06.027_bb0030","doi-asserted-by":"crossref","first-page":"1906832","DOI":"10.1002\/smll.201906832","article-title":"Codelivery of anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dual-sensitive micelles for enhanced tumor Chemoimmunotherapy","volume":"16","author":"Su","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2021.06.027_bb0035","doi-asserted-by":"crossref","first-page":"120380","DOI":"10.1016\/j.biomaterials.2020.120380","article-title":"Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy","volume":"263","author":"Joo","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.06.027_bb0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.jconrel.2021.06.027_bb0045","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","article-title":"Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.jconrel.2021.06.027_bb0050","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.jconrel.2021.06.027_bb0055","doi-asserted-by":"crossref","first-page":"11041","DOI":"10.1021\/acsnano.8b05189","article-title":"Breast cancer chemo-immunotherapy through liposomal delivery of an immunogenic cell death stimulus plus interference in the IDO-1 pathway","volume":"12","author":"Lu","year":"2018","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.jconrel.2021.06.027_bb0060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2021.06.027_bb0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fcell.2018.00038","article-title":"Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors","volume":"6","author":"Cassetta","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"issue":"17","key":"10.1016\/j.jconrel.2021.06.027_bb0070","doi-asserted-by":"crossref","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti\u2013PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"389","key":"10.1016\/j.jconrel.2021.06.027_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage\u2013mediated resistance pathway in anti\u2013PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2021.06.027_bb0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2021.06.027_bb0085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jfma.2019.10.019","article-title":"Functions and therapeutic targets of siglec-mediated infections, inflammations and cancers","volume":"120","author":"Lin","year":"2021","journal-title":"J. Formosan Med. Assoc."},{"issue":"6","key":"10.1016\/j.jconrel.2021.06.027_bb0090","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cell.2016.01.043","article-title":"Communication by extracellular vesicles: where we are and where we need to go","volume":"164","author":"Tkach","year":"2016","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.jconrel.2021.06.027_bb0095","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1016\/j.biomaterials.2014.03.022","article-title":"The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid\u2013octadecylamine conjugate","volume":"35","author":"She","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.06.027_bb0100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.actbio.2019.05.030","article-title":"Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy","volume":"92","author":"Qiu","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2021.06.027_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2019.01.048","article-title":"Nucleus-targeted nano delivery system eradicates cancer stem cells by combined thermotherapy and hypoxia-activated chemotherapy","volume":"200","author":"Li","year":"2019","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.jconrel.2021.06.027_bb0110","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1021\/mp5002312","article-title":"iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors","volume":"11","author":"Zhao","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.06.027_bb0115","doi-asserted-by":"crossref","first-page":"118005","DOI":"10.1016\/j.lfs.2020.118005","article-title":"Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells","author":"Khosravi","year":"2020","journal-title":"Life Sciences"},{"issue":"3","key":"10.1016\/j.jconrel.2021.06.027_bb0120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/cells9030555","article-title":"Cancer stem cells: devil or savior\u2014looking behind the scenes of immunotherapy failure","volume":"9","author":"Castagnoli","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2021.06.027_bb0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.imlet.2019.03.004","article-title":"Interactions between cancer stem cells, immune system and some environmental components: friends or foes?","volume":"208","author":"Vahidian","year":"2019","journal-title":"Immunol. Lett."},{"issue":"5","key":"10.1016\/j.jconrel.2021.06.027_bb0130","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1208\/s12249-019-1385-0","article-title":"Dual-ligand modification of PEGylated liposomes used for targeted doxorubicin delivery to enhance anticancer efficacy","volume":"20","author":"Li","year":"2019","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.jconrel.2021.06.027_bb0135","article-title":"Leishmania donovani cell surface sialoglycans regulate susceptibility for siglec mediated macrophage invasion and parasite survival","volume":"1","author":"Karmakar","year":"2012","journal-title":"Journal of Molecular Biochemistry"},{"issue":"23","key":"10.1016\/j.jconrel.2021.06.027_bb0140","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMcibr061443","article-title":"A better way for a cancer cell to die","volume":"354","author":"Lake","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2021.06.027_bb0145","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bbrc.2017.10.058","article-title":"Fluorescence-labeled liposome accumulation in injured colon of a mouse model of T-cell transfer-mediated inflammatory bowel disease","volume":"494","author":"Yamasaki","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2021.06.027_bb0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijpharm.2017.03.034","article-title":"Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity","volume":"523","author":"Zhou","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2021.06.027_bb0155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijpharm.2018.06.021","article-title":"Targeted delivery of pixantrone to neutrophils by poly (sialic acid)-p-octadecylamine conjugate modified liposomes with improved antitumor activity","volume":"547","author":"Luo","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2021.06.027_bb0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"issue":"12","key":"10.1016\/j.jconrel.2021.06.027_bb0165","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2021.06.027_bb0170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4161\/onci.1.2.19026","article-title":"Trial watch: chemotherapy with immunogenic cell death inducers","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.jconrel.2021.06.027_bb0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.jconrel.2021.06.027_bb0180","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.jconrel.2021.06.027_bb0185","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/wnan.85","article-title":"In vivo near-infrared fluorescence imaging of cancer with nanoparticle-based probes","volume":"2","author":"He","year":"2010","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2021.06.027_bb0190","first-page":"2412","article-title":"Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology","volume":"38","author":"Prabhakar","year":"2013","journal-title":"AACR"},{"issue":"6","key":"10.1016\/j.jconrel.2021.06.027_bb0195","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.cell.2017.08.031","article-title":"Converting cold into hot tumors by combining immunotherapies","volume":"170","author":"Haanen","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2021.06.027_bb0200","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Vareki","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2021.06.027_bb0205","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.jconrel.2021.06.027_bb0210","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djz208","article-title":"Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach","volume":"112","author":"Bareche","year":"2020","journal-title":"JNCI"},{"issue":"28","key":"10.1016\/j.jconrel.2021.06.027_bb0215","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1200\/JCO.2005.07.501","article-title":"Proliferation marker Ki-67 in early breast cancer","volume":"23","author":"Urruticoechea","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2021.06.027_bb0220","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1039\/C9BM01732A","article-title":"Sialic acid-conjugate modified liposomes targeting neutrophils for improved tumour therapy","volume":"8","author":"Li","year":"2020","journal-title":"Biomaterials Science"},{"issue":"4","key":"10.1016\/j.jconrel.2021.06.027_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.02.009","article-title":"Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets","volume":"35","author":"Cassetta","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2021.06.027_bb0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","article-title":"Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer","volume":"58","author":"Davis","year":"2016","journal-title":"Oral Oncol."},{"issue":"7","key":"10.1016\/j.jconrel.2021.06.027_bb0235","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1596004","article-title":"Interaction of tumor-associated macrophages and cancer chemotherapy","volume":"8","author":"Larionova","year":"2019","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.jconrel.2021.06.027_bb0240","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1084\/jem.20150295","article-title":"The interaction of anticancer therapies with tumor-associated macrophages","volume":"212","author":"Mantovani","year":"2015","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2021.06.027_bb0245","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1021\/acs.biomac.8b00305","article-title":"Glycocalyx-mimicking nanoparticles improve anti-PD-L1 cancer immunotherapy through reversion of tumor-associated macrophages","volume":"19","author":"Zhang","year":"2018","journal-title":"Biomacromolecules"},{"issue":"4","key":"10.1016\/j.jconrel.2021.06.027_bb0250","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12441","article-title":"Anti-cancer therapy with TNF \u03b1 and IFN \u03b3: a comprehensive review","volume":"51","author":"Shen","year":"2018","journal-title":"Cell Prolif."},{"issue":"5","key":"10.1016\/j.jconrel.2021.06.027_bb0255","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2021.06.027_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/celldisc.2017.10","article-title":"Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation","volume":"3","author":"Shi","year":"2017","journal-title":"Cell Discov."},{"issue":"19","key":"10.1016\/j.jconrel.2021.06.027_bb0265","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.jconrel.2021.06.027_bb0270","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ejpb.2014.10.006","article-title":"Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells","volume":"88","author":"Yang","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2021.06.027_bb0275","series-title":"Breast Cancer Stem Cell Antigens as Targets for Immunotherapy, Seminars in Immunology","first-page":"101386","author":"Quaglino","year":"2020"},{"issue":"18","key":"10.1016\/j.jconrel.2021.06.027_bb0280","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1073\/pnas.1818210116","article-title":"Cancer stemness, intratumoral heterogeneity, and immune response across cancers","volume":"116","author":"Miranda","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2021.06.027_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-9966-30-30","article-title":"Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice","volume":"30","author":"Sun","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jconrel.2021.06.027_bb0290","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1073\/pnas.0705395105","article-title":"Progenitor\/stem cells give rise to liver cancer due to aberrant TGF-\u03b2 and IL-6 signaling","volume":"105","author":"Tang","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2021.06.027_bb0295","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41565-020-00793-0","article-title":"A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells","volume":"16","author":"Shen","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2021.06.027_bb0300","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jconrel.2019.01.006","article-title":"Glucose-linked sub-50-nm unimer polyion complex-assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1-overexpressing breast cancer stem-like cells","volume":"295","author":"Yi","year":"2019","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592100314X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592100314X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:01:14Z","timestamp":1772737274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592100314X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":60,"alternative-id":["S016836592100314X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.06.027","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}